Curriculum Vitae

PERSONAL INFORMATION

Christof Schaefer

WORK EXPERIENCE May 1988–Present

Head of institute Pharmakovigilanzzentrum Embryonaltoxikologie, Charité Universitätsmedizin Berlin, (Germany) Related document(s):

EDUCATION AND TRAINING May 1981–May 1988

Paediatrician

Related document(s): ADDITIONAL INFORMATION Expertise

Publications

Drug safety in pregnancy, Clinical teratology, Drug safety during lactation, Risk communication, Paediatrics, Padiatric pharmacology

•Oppermann M, Padberg S, Kayser A, Weber-Schoendorfer C, Schaefer C. Angiotensin-II-receptor-1antagonist fetopathy - Risk assessment, critical time period, and vena cava thrombosis as a possible new feature. Br J Clin Pharmacol 2013; 75: 822-30. •Padberg S, Schaefer C. Antiinfektiva während der Schwangerschaft und im Wochenbett. In Friese K. et al. (Hrg): Infektionserkrankungen der Schwangeren und des Neugeborenen. Springer-Verlag, Berlin 2013. •Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. Allopurinol use during pregnancy outcome of 31 prospectively ascertained cases and a phenotype possibly indicative for teratogenicity. PLoS ONE 2013; 8(6): e66637. •Habermann F, Fritzsche J, Fuhlbrück F, Wacker E, Allignol A, Weber-Schoendorfer C, Meister R, Schaefer C. Atypical antipsychotic drugs and pregnancy outcome: A prospective cohort study. J Clin Psychopharmacology 2013; 33: 453-62. •Schaefer C. Arzneimittelprojekt Embryotox - Sicherheit für Mutter und Kind. Dtsch Ärztebl 2013; 110: 1048. •Wacker E, Schaefer C, Meister R. No Chance for Bias - Methodological Considerations for Drug Risk Assessment in Pregnancy (Abstract). Reprod Toxicol 2013; 37: 85-86. •Hoeltzenbein M, Stieler K, Panse M, Wacker E, Schaefer C. First Trimester Use of Allopurinol Outcome of 31 Prospectively Ascertained Pregnancies and a Phenotype Possibly Indicative for Teratogenicity (Abstract). Reprod Toxicol 2013; 37: 86. •Weber-Schoendorfer C, Oppermann M, Schaefer C. Pregnancy outcomes and infant‘s development after maternal TNF-alpha inhibitor therapy in pregnancy – design of an observational multicenter cohort study (Abstract). Reprod Toxicol 2013; 37: 86. 2012 •Fritzsche J, Pilch A, Mury D, Schaefer C, Weber-Schoendorfer C. Infliximab and Adalimumab Use During Breastfeeding. J Clin Gastroenterol 2012; 46 (8): 718-9. •Borisch C, Kayser A, Weber-Schoendorfer C, Schaefer C. Severe neutropenia in a newborn after clozapine therapy during pregnancy (Abstract). Reprod Toxicol 2012; 34: 158. •Schaefer C, Weber-Schöndorfer C. Aktuelle Aspekte zum Arzneimitteleinsatz in Schwangerschaft und Stillzeit. Arzneimitteltherapie 2012; 30: 383-90. •Dostal M, Weber-Schoendorfer C, Sobesky J, Schaefer C. Pregnancy outcome following use of

7/5/14

© European Union, 2002-2014 | http://europass.cedefop.europa.eu

Page 1 / 5

Curriculum Vitae

Christof Schaefer

levodopa, pramipexole, ropinirole and rotigotine for restless legs syndrome during pregnancy: a case series. Eur J Neurol 2012 Oct 22. doi:10.1111/ene.12001. [Epub ahead of print]. •Schaefer C, Oppermann M, Wacker E, Weber-Schoenfelder C. Arzneimitteltherapiesicherheit in der Schwangerschaft – das Embryotox-Projekt. ZEFQ 2012; 106: 723-8. •Artmann T, Hönig A, Wirbelauer J, Schaefer C, Schelling P, Kranke P. Stillen nach Narkosen: Ist eine Stillpause obligat? Geburtsh Frauenheilk 2012; 72, 983-987. •Oppermann M, Fritzsche J, Weber-Schoendorfer C, Keller-Stanislawski B, Allignol A, Meister R, Schaefer C. A-(H1N1)v 2009: A controlled observational prospective cohort study on vaccine safety in pregnancy. Vaccine 2012; 30: 4445-52. •Fritzsche J, Borisch C, Schaefer C. Case Report: High Chromium and Cobalt Levels in a Pregnant Patient with Bilateral Metal-on-Metal Hip Arthroplasties. Clin Orthop Relat Res 2012 Aug;470(8):232531. Erratum: Clin Orthop Relat Res 2012 Jul 14. •Hoeltzenbein M, Elefant E, Vial T, Finkel-Pekarsky V, Stephens S, Clementi M, Allignol A, WeberSchoendorfer C, Schaefer C. Teratogenicity of mycophenolate confirmed in a prospective study of the European Network of Teratology Information Services. Am J Med Genet A 2012; 158A: 588-96. •Schaefer C, Hoffmann-Walbeck P. Intoxikationen bei Schwangeren. Med Klin Intensivmed Notfmed 2012; 107: 118-22. •Tümmler G, Schaefer C. Duogynon: Angeborene Fehlbildungen nach Applikation der ÖstrogenProgesteron-Kombination in der Schwangerschaft – Auswertung einer retrospektiven Fallserie. Bulletin zur Arzneimittelsicherheit (BfArM, Paul-Ehrlich-Institut) 2012; 4: 20-23. •Rohde A, Dorsch VM, Schaefer C. Die Behandlung mit Psychopharmaka in der Schwangerschaft – So wenig wie möglich, aber so viel wie nötig. Fortschr Neurol Psychiatr 2012; 80: 227-40. •Reuvers N, Vial T, Schaefer C et al. Pregnancy outcome after first trimester exposure to malarone (atovaquone-proguanil): a prospective case-series (Abstract). Birth Defects Research A 2012; 94: 329 •Hoeltzenbein M, Weber-Schoendorfer C, Borisch C, Allignol A, Meister R, Schaefer C. Pregnancy outcome after paternal exposure to azathioprine/6-mercaptopurine. Reprod Toxicol 2012; 34: 364-9. •Schaefer C. Arzneimittelsicherheit in der Schwangerschaft – eine Utopie? Geburtsh Frauenheilk 2012; 72: 701-2. •Schaefer C, Weber-Schoendorfer C. Aktuelle Aspekte zum Arzneimitteleinsatz in Schwangerschaft und Stillzeit. Krankenhauspharmazie 2012; 33: 347-55. •Schaefer C. Paradigm change in pain therapy: Do we take leave of paracetamol in pregnancy? (Abstract) Reprod Toxicol 2012; 34: 150. 2011 •Weber-Schoendorfer C, Fritzsche J, Schaefer C. Pregnancy outcomes in women exposed to adalimumab or infliximab. The Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy (Abstract). Reprod Toxicol 2011; 31: 267-8. •Panchaud A, Csajka C, Merlob P, Schaefer C et al. Pregnancy Outcome Following Exposure to Topical Retinoids: A Multicenter Prospective Study. J Clin Pharmacol 2011 Dec 15. [Epub ahead of print]. •Hoeltzenbein M, Supcun-Ritzler S, Langthaler M, Daumer-Haas C, Schaefer C. Lacosamide during pregnancy: Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy (Abstract). Reprod Toxicol 2011; 31: 259. •Oppermann M, Padberg S, Schaefer C. Angiotensin II-receptor 1-antagonists during 2nd or 3rd trimester: Evaluation of a case series from the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy (Abstract). Reprod Toxicol 2011; 31: 264. •Hultzsch S, Weber-Schoendorfer, Schaefer C. Pregnancy outcomes after exposure to etanercept (Abstract). Reprod Toxicol 2011; 31: 260. •Fritzsche J, Mury D, Wintgens KF Pilch A, Schaefer C, Weber-Schoendorfer C. Infliximab and adalimumab use during lactation (Abstract). Reprod Toxicol 2011; 31: 258. •Schaefer C. Drug Safety in Pregnancy – Utopia or achievable prospect? Risk information, risk research, advocacy in Teratology Information Services. Congenit Anom 2011; 51: 6-11. •Schaefer C, Wieacker P. Teratogene Faktoren. In Murken J, Grimm T, Holinski-Feder (Hrg): Humangenetik, 8. Aufl. Thieme-Verlag 2011. •Kranke P, Frambach T, Schelling Ph, Wirbelauer J, Schaefer C, Stamer U. Stillen nach Narkosen: Ist eine Stillpause obligat? Anasthesiol Intensivmed Notfallmed Schmerzther 2011; 46: 304-11. •Schaefer C, Sartane und ACE-Hemmer schaden dem Feten, Frauenarzt 2011; 52:2-3.

7/5/14

© European Union, 2002-2014 | http://europass.cedefop.europa.eu

Page 2 / 5

Curriculum Vitae

Christof Schaefer

•Regitz-Zagrosek V, Seeland U, Geibel-Zehender A, Gohlke-Bärwolf C, Kruck I, Schaefer C. HerzKreislauf-Erkrankungen in der Schwangerschaft. Dtsch Ärztebl 2011;108:267-73. 2010 •Hoeltzenbein M, Elefant E, Garayt C, Ornoy A, Clementi M, Manakova E, Merlob P, Rodríguez-Pinilla E, Rothuizen L, Smorlesi C, te Winkel B, de Santis M, Stephens S, Vial T, Weber-Schoendorfer C, Schaefer C. Maternal exposure to mycophenolate mofetil in pregnancy – Results of the ENTIS collaborative study (Abstract). Reprod Toxicol 2010; 30: 228 •Habermann F, Karbaum F, Meister R, Weber-Schoendorfer C, Schaefer C. Pregnancy outcome after exposure to second-generation antipsychotics (Abstract). Reprod Toxicol 2010; 30: 228. •Fritzsche J, Borisch C, Weber-Schoendorfer C, Schaefer C. High levels of chromium and cobalt in a pregnant patient with metal-on-metal hip arthroplasty (Abstract). Reprod Toxicol 2010; 30: 237-8. •Dostal M, Felberg M, Weber-Schoendorfer C, Schaefer C. Treatment of restless legs syndrome during pregnancy (Abstract). Reprod Toxicol 2010;30:236-7. •Schaefer C , Fritzsche J, Karbaum F, Allignol A, Meister R, Weber-Schoendorfer C. 2009 H1N1 Vaccination in Pregnancy – Experience of the European Network of Teratology Information Services (ENTIS) (Abstract). Reprod Toxicol 2010; 30: 220. •Rohde A, Schaefer C. Psychopharmakotherapie und psychiatrische Begleitung in Schwangerschaft und Stillzeit. In: Möller, Laux, Kapfhammer (Hrg.): Psychiatrie und Psychotherapie, 4. Aufl. Springer, Heidelberg 2010. •Schaefer C. Risiken der Sartantherapie in der Schwangerschaft. Monatsschr Kinderheilk 2010; 12: 5. •Hoyer AC, Henrich W, Schaefer C, Spors B, Czernik C. Coumarin Embryopathy after intrauterine exposure to Vitamin K antagonists within the first 10 post-menstrual weeks. Ultraschall in Med 2010; 31: 411–413 •Hoeltzenbein M, Weber-Schoendorfer C, Padberg S, Borisch C, Schaefer C. Paternal exposure to azathioprine/6-mercaptopurine - Experience of Berlin TIS (Abstract). Reprod Toxicol 2010; 30: 238-9. Poster präsentiert auf der ENTIS-Konferenz 2010 in Barcelona. •Rabe T, Ludwig M, Goeckenjan M, Schaefer C. Was bei Langzeitkontrazeption post partum zu beachten ist. Gyne 2010; 1: 19-22. •Schaefer C, Meister R, Weber-Schoendorfer C. Isotretinoin exposure and pregnancy outcome- an observational study of the Berlin Institute for Clinical teratology and Drug Risk Assessment in Pregnancy. Arch Gynecol Obstet 2010; 281: 221-7. •Henze T, Janzen R, Schumm F, Melms A, Sieb J, Köhler W, Heidenreich F, Tackenberg B, WeberSchöndorfer C. Immuntherapie bei Myasthenia gravis und Lambert-Eaton Syndrom. Teil 1: Medikamentöse Immunsuppression. Akt Neurol 2010;37 (10):505-517. 2009 •Rabe T, Ludwig M, Goeckenjan M, Schaefer C. Methoden der Kontrazeption im Wochenbett und Anwendungseinschränkungen bei stillenden Frauen. Gyne 2009; 12: 19-23. •Schaefer C, Rohde A. So wenig wie möglich, soviel wie nötig. ÄP Neurologie Psychiatrie 2009; 11: 24-7. •Weber-Schoendorfer C, Schaefer C. Multiple Sclerosis, immunomodulators and pregnancy outcome. A prospective observational study. Mult Scler 2009 15:1037-42. •Schaefer C, Meister R, Wentzeck R, Weber-Schoendorfer C. Fetal outcome after technetium scintigraphy in early pregnancy. Reprod Toxicol 2009; 28: 161-166. •Schaefer C, Weber-Schoendorfer C. Pharmakotherapie in der Schwangerschaft, CME Weiterbildung. Internist 2009; 50: 455-66. •Becker C, Stichtenoth D, Wichmann M, Schaefer C, Szinicz L. Blood donors on medication. An approach to minimize drug burden for recipients of blood products and to limit deferral of donors. Transfus Med Hemother 2009; 36: 107-13. •Hoeltzenbein M, Weber-Schoendorfer C, Schaefer C. Mycophenolate mofetil – a teratogenic drug? Experience of the Berlin Institute of Clinical teratology and drug risk assessment during pregnancy (Abstract). Medizinische Genetik 2009; 21: 78-9. •Schaefer C. Topische und systemische Therapie in der Schwangerschaft (Abstract). JDDG 2009; 7 (Suppl. 4): 43. •Jürgens T, Schaefer C, May A. Treatment of cluster headache in pregnancy and lactation. Cephalalgia 2009; 29:391-400. •Schaefer C. Arzneimittel in der Schwangerschaft und Stillperiode. In: Reiss M (Hrg): Facharztwissen

7/5/14

© European Union, 2002-2014 | http://europass.cedefop.europa.eu

Page 3 / 5

Curriculum Vitae

Christof Schaefer

HNO. Springer, Heidelberg 2009. •Schaefer C. Arzneitherapie in Schwangerschaft und Stillzeit. In Arzneimittelkommission der deutschen Ärzteschaft (Hrg): Arzneiverordnungen, 22. Aufl. MMI, Neu-Isenburg 2009. •Rabe T, Ludwig M, Goeckenjan M, Schaefer C. Welche Verhütung ist im Anschluss an eine Geburt und in der Stillzeit effektiv? Gyne 2009; 8: 19-21. 2008 •Weber-Schoendorfer C, Hannemann D, Meister R, Eléfant E, Cuppers-Maarschalkerweerd B, Arnon J, Vial T, Rodriguez-Pinilla E, Clementi M, Robert-Gnansia E, De Santis M, Malm H, Dolivo A, Schaefer C. The safety of calcium channel blockers during pregnancy. A prospective, multicenter, observational study. Reprod Toxicol 2008; 26: 24-30. •Schaefer C, Ornoy A, Clementi M, Meister R, Weber-Schoendorfer C. Using observational cohort data for studying drug effects on pregnancy outcome - Methodological considerations. Reprod Toxicol 2008; 26: 36-41. •Meister R, Schaefer C. Statistical methods for estimating the probability of spontaneous abortion in observational studies. – Analyzing pregnancies exposed to coumarin derivatives. Reprod Toxicol 2008; 26: 31-35. •Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol 2008; 26: 19-23. •Diav-Citrin O, Shechtman S, Weinbaum D, Wajnberg R, Avgil M, Arnon J, Di Gianantonio E, Clementi M, Weber-Schoendorfer C, Schaefer C & Ornoy A. Paroxetine and Fluoxetine in Pregnancy: a prospective, multi-center, controlled, observational study. Br J Clin Pharmacol 2008; 65: 695-705. •Rohde A, Schaefer C. Betreuung schwangerer und stillender Patientinnen – Psychopharmakotherapie und psychiatrische Begleitung. In: Möller, Laux, Kapfhammer (Hrg.): Psychiatrie und Psychotherapie, 3. Aufl. S. 1235-44. Springer, Heidelberg 2008. •Weber-Schoendorfer C, Schaefer C. [Trastuzumab in pregnancy] Letter to the Editor. Reprod Toxicol 2008; 25: 390-1. •Panchaud A, Stahl B, Schaefer C, Berlin M, De Santis M, Vial T, Ieri A, Malm H, Eleftheriou G, Buclin T. Topical retinoids exposure during the first trimester of pregnancy (Abstract). Posterpräsentation. World Conference on Clinical Pharmacology and Therapeutics. Quebec, Canada 2008. •Schaefer C. 50 Jahre nach Contergan - Eine Betrachtung zur Arzneimittelsicherheit in der Schwangerschaft heute. Arzneiverordnung in der Praxis 2008; 35: 65-6. •Hoeltzenbein M, Weber-Schoendorfer C, von Stackelberg L, Schaefer C. Paternal exposure to drugs – Is there an increased risk for congenital abnormalities? Experience of the Berlin Institute of Clinical Teratology and Drug Risk Assessment during Pregnancy (Abstract). Med Genetik 2008; 20: 166. •Rabe T, Ludwig M, Bitzer J, Geisthövel F, Schaefer C. Schwangerschaften unter verschiedenen kontrazeptiven Methoden. J Reproduktionsmed Endokrinol 2008; 5: 138-146. •Rabe T, Ludwig M, Bitzer J, Geisthövel F, Schaefer C. Terato- bzw. Mutagenität von Arzneimitteln: Wenn unter Anwendung von Kontrazeptiva eine Schwangerschaft eintritt (zertifizierte Fortbildung). Gyne 2008; 5: 1-8. •Padberg S, Weber-Schoendorfer C, Schaefer C. Lamotrigine during lactation (Abstract). Reprod Toxicol 2008; 26: 70/71. •Weber-Schoendorfer C, Schaefer C. Monoclonal antibody therapy during pregnancy – Experience of the Berlin Teratology Information Service (Abstract). Reprod Toxicol 2008; 26: 75. •Weber-Schoendorfer C, Schaefer C. Multiple sclerosis – effects of immunomodulatory therapy on pregnancy outcome: An observational study of the Teratology Information Service Berlin, Germany (Abstract). Birth Def Res A 2008; 82: 298. •Hoeltzenbein M, Weber-Schoendorfer C, v. Stackelberg L, Schaefer C. Paternal exposure to drugs – Is there an increased risk for congenital abnormalities? Experience of the Berlin Institute for Clinical Teratology and Drug Risk Assessment during Pregnancy (Abstract). Reprod Toxicol 2008; 26: 64. 2007 •Goldstein LH, Dolinsky G, Greenberg R, Schaefer C, Cohen-Kerem R, Diav-Citrin O, Malm H, Reuvers-Lodewijks ME, Rost van Tonningen-van Driel MM, Arnon J, Ornoy A, Clementi M, Di Gianantonio E, Koren G, Braunstein R, Berkovitch M. Pregnancy outcome of women exposed to azathioprine during pregnancy. Birth Defects Research A 2007; 79: 696-701. •Kallinich T, Haffner D, Niehues T, Huss K, Lainka E, Neudorf U, Schaefer C, Stojanov S, Timmann C, Keitzer R, Ozdogan H, Ozen S. Colchicine use in children and adolescents with Familial

7/5/14

© European Union, 2002-2014 | http://europass.cedefop.europa.eu

Page 4 / 5

Curriculum Vitae

Christof Schaefer

Mediterranean fever. Literature review and consensus statement. Pediatrics 2007; 119: e474-83. •Schaefer C. Off-label-Use von Medikamenten in der Schwangerschaft. Der Frauenarzt 2007; 48: 205. •Meister R, Schaefer C. Spontaneous abortion rates: Unbiased statistical estimation – with coumarins as an example (Abstract). Reprod Toxicol 2007; 24: 64. Projects Memberships

Safety of H1N1 vaccination during pregnancy

Scientific Board of European Network of Teratology Information Services (ENTIS)

Other Relevant Information

7/5/14

© European Union, 2002-2014 | http://europass.cedefop.europa.eu

Page 5 / 5